Patricia Mangan
Nurse Practitioner · Philadelphia, PANPI 1629288964
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $263,607 of the $360,301 with a category attached, or 73.2%. 17 manufacturers reported payments, led by Johnson & Johnson at 50.8% of the total. Reporting peaked in 2022 at $126,167 and has fallen 57.8% since, to $53,207 in 2025. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 475 payments — averaging $758.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$183K
- E.r. Squibb & Sons, L.L.C.$57K
- GSK$57K
- Karyopharm Therapeutics Inc.$20K
- Takeda Pharmaceuticals U.S.A., Inc.$20K
- Bristol Myers Squibb$9K
- plus $15K from 11 others
What the payments were for
- Consulting fees$35,48610%
- Speaking & faculty fees$263,60773%
- Grants$1,5000%
- Travel & lodging$49,37514%
- Food & beverage$10,3343%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 209 | $182,910 |
| E.r. Squibb & Sons, L.L.C. | 79 | $57,430 |
| GSK | 66 | $56,597 |
| Karyopharm Therapeutics Inc. | 32 | $20,148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $19,666 |
| Bristol Myers Squibb | 22 | $8,811 |
| Sanofi | 12 | $8,073 |
| Legend Biotech USA Inc. | 1 | $1,375 |
| AstraZeneca | 11 | $1,324 |
| Novartis | 1 | $1,157 |
| Genentech, Inc. | 1 | $1,050 |
| Pfizer | 2 | $972 |
| Taiho Oncology, Inc. | 7 | $422 |
| Amgen | 1 | $313 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Genmab U.S., Inc. | 1 | $20 |
| Janssen Research & Development, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$360,301 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 105 | $1,659,790 |
| NinlaroIxazomib Citrate | 49 | $595,729 |
| BrukinsaZanubrutinib | 41 | $563,138 |
| TasignaNilotinib Hcl | 13 | $121,151 |
| EliquisApixaban | 44 | $30,862 |
| Imatinib Mesylate | 13 | $18,587 |
| OxycontinOxycodone Hcl | 25 | $7,593 |
| XareltoRivaroxaban | 14 | $7,504 |
| ValacyclovirValacyclovir Hcl | 156 | $4,785 |
| Acyclovir | 108 | $2,944 |
| Opium Tincture | 12 | $2,798 |
| Morphine Sulfate ErMorphine Sulfate | 26 | $2,340 |
| CholestyramineCholestyramine (With Sugar) | 44 | $1,764 |
| Dexamethasone | 56 | $945 |
| Oxycodone Hcl | 44 | $889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $19,666 | $595,72949 claims |
| NovartisTasigna | $1,157 | $121,15113 claims |
| PfizerEliquis | $972 | $30,86244 claims |
| Johnson & JohnsonXarelto | $182,910 | $7,50414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Philadelphia
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Carolyn GrandePhiladelphia$71K
- Faith MutalePhiladelphia$62K
- Frances RogersPhiladelphia$46K
- Meghan GarabedianPhiladelphia$30K
- Victoria SherryPhiladelphia$10K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.